Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 180

1.

TAVI for Pure Native Aortic Regurgitation: Are We There Yet?

Arias EA, Bhan A, Lim ZY, Mullen M.

Interv Cardiol. 2019 Feb;14(1):26-30. doi: 10.15420/icr.2018.37.1. Review.

2.

Erratum to: Common and Uncommon CTO complications.

Rigger J, Hanratty CG, Walsh SJ.

Interv Cardiol. 2019 Feb;14(1):48. doi: 10.15420/icr.2018.35.1.

3.

Why Did COAPT Win While MITRA-FR Failed? Defining the Appropriate Patient Population for MitraClip.

Atianzar K, Zhang M, Newhart Z, Gafoor S.

Interv Cardiol. 2019 Feb;14(1):45-47. doi: 10.15420/icr.2018.40.1. Review.

4.

Device-Related Thrombus After Left Atrial Appendage Closure.

Garot P, Cormier B, Horvilleur J.

Interv Cardiol. 2019 Feb;14(1):42-44. doi: 10.15420/icr.2018.21.3. Review.

5.

Patent Foramen Ovale Closure in 2019.

Giblett JP, Abdul-Samad O, Shapiro LM, Rana BS, Calvert PA.

Interv Cardiol. 2019 Feb;14(1):34-41. doi: 10.15420/icr.2018.33.2. Review.

6.

How to Make the TAVI Pathway More Efficient.

Tchetche D, de Biase C, Brochado B, Mastrokostopoulos A.

Interv Cardiol. 2019 Feb;14(1):31-33. doi: 10.15420/icr.2018.28.2. Review.

7.

Cerebral Embolic Protection in TAVI: Friend or Foe.

Teitelbaum M, Kotronias RA, Sposato LA, Bagur R.

Interv Cardiol. 2019 Feb;14(1):22-25. doi: 10.15420/icr.2018.32.2. Review.

8.

Large-bore Vascular Closure: New Devices and Techniques.

van Wiechen MP, Ligthart JM, Van Mieghem NM.

Interv Cardiol. 2019 Feb;14(1):17-21. doi: 10.15420/icr.2018.36.1. Review.

9.

Contemporary Management of Stent Failure: Part One.

Pal N, Din J, O'Kane P.

Interv Cardiol. 2019 Feb;14(1):10-16. doi: 10.15420/icr.2018.39.1. Review.

10.

OCT-guided Percutaneous Coronary Intervention in Bifurcation Lesions.

Longobardo L, Mattesini A, Valente S, Di Mario C.

Interv Cardiol. 2019 Feb;14(1):5-9. doi: 10.15420/icr.2018.17.2. Review.

11.

Foreword.

Kennon S.

Interv Cardiol. 2019 Feb;14(1):4. doi: 10.15420/icr.2019.14.1.FO1. No abstract available.

12.

Alternate Access for TAVI: Stay Clear of the Chest.

Overtchouk P, Modine T.

Interv Cardiol. 2018 Sep;13(3):145-150. doi: 10.15420/icr.2018.22.1. Review.

13.

Annular Rupture During Transcatheter Aortic Valve Implantation: Predictors, Management and Outcomes.

Coughlan JJ, Kiernan T, Mylotte D, Arnous S.

Interv Cardiol. 2018 Sep;13(3):140-144. doi: 10.15420/icr.2018.20.2. Review.

14.

Delayed Coronary Occlusion After Transcatheter Aortic Valve Implantation: Implications for New Transcatheter Heart Valve Design and Patient Management.

Jabbour RJ, Tanaka A, Colombo A, Latib A.

Interv Cardiol. 2018 Sep;13(3):137-139. doi: 10.15420/icr.2018.24.2. Review.

15.

ORBITA: What Goes Around, Comes Around… Or Does It?

Jackson M, Zaman A.

Interv Cardiol. 2018 Sep;13(3):135-136. doi: 10.15420/icr.2018.18.2. Review.

16.
17.

FFRCT for Complex Coronary Artery Disease Treatment Planning: New Opportunities.

Leipsic J, Weir-McCall J, Blanke P.

Interv Cardiol. 2018 Sep;13(3):126-128. doi: 10.15420/icr.2018.14.3. Review.

18.

Common and Uncommon CTO Complications.

Rigger J, Hanratty CG, Walsh SJ.

Interv Cardiol. 2018 Sep;13(3):121-125. doi: 10.15420/icr.2018.10.2. Review. Erratum in: Interv Cardiol. 2019 Feb;14(1):48.

19.

Risk Stratification in Patients with Coronary Artery Disease: A Practical Walkthrough in the Landscape of Prognostic Risk Models.

Buccheri S, D'Arrigo P, Franchina G, Capodanno D.

Interv Cardiol. 2018 Sep;13(3):112-120. doi: 10.15420/icr.2018.16.2. Review.

20.

'Primary' Microvascular Angina: Clinical Characteristics, Pathogenesis and Management.

Lanza GA, De Vita A, Kaski JC.

Interv Cardiol. 2018 Sep;13(3):108-111. doi: 10.15420/icr.2018.15.2. Review.

Supplemental Content

Loading ...
Support Center